Drug firm Jubilant Life Sciences Friday said its arm Drug Discovery and Development Solutions Ltd (DDDSL), Singapore, has entered into an agreement to acquire 10 per cent stake in Inipharm Inc USA for USD 534.20 (around Rs 37,300).
DDDSL Singapore, a wholly-owned subsidiary of the company, has entered into a stock purchase agreement for acquiring 10 per cent shares of common stock of Inipharm Inc USA for a total purchase consideration of USD 534.20 only.
Shares of Jubilant Life Sciences Friday were trading at Rs 762.30 per scrip on the BSE, up 3.06 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app